SAB Biotherapeutics Unveils Positive Phase 1 Data for SAB-142 in Type 1 Diabetes

Reuters11-04

<a href="https://laohu8.com/S/SABS">SAB Biotherapeutics</a> Unveils Positive Phase 1 Data for SAB-142 in Type 1 Diabetes

SAB Biotherapeutics Inc. has announced that new data on its lead candidate, SAB-142, will be presented at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD), taking place November 5-8, 2025, in Montréal, Canada. SAB-142, a fully human anti-thymocyte globulin (hATG), is being developed for the treatment of Stage 3 autoimmune type 1 diabetes. Presentations will include data from a Phase 1 study highlighting the therapy's clinically validated, multi-specific mechanism of action and sustained immunomodulation, as well as its favorable safety profile, with no serum sickness or anti-drug antibodies observed at the target dose. Additional presentations will cover a novel pharmacokinetic assay for SAB-142, its binding specificities, and specimen quality in multicenter clinical trials. The results are scheduled to be presented during the conference and have not yet been publicly disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567864-en) on November 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580732458?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580732458","market":"us","top_or_hot":-1,"title":"SAB Biotherapeutics Unveils Positive Phase 1 Data for SAB-142 in Type 1 Diabetes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SABS\">SAB Biotherapeutics</a> Unveils Positive Phase 1 Data for SAB-142 in Type 1 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SABSW\">SAB Biotherapeutics</a> Inc. has announced that new data on its lead candidate, SAB-142, will be presented at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD), taking place November 5-8, 2025, in Montréal, Canada. SAB-142, a fully human anti-thymocyte globulin (hATG), is being developed for the treatment of Stage 3 autoimmune type 1 diabetes. Presentations will include data from a Phase 1 study highlighting the therapy's clinically validated, multi-specific mechanism of action and sustained immunomodulation, as well as its favorable safety profile, with no serum sickness or anti-drug antibodies observed at the target dose. Additional presentations will cover a novel pharmacokinetic assay for SAB-142, its binding specificities, and specimen quality in multicenter clinical trials. The results are scheduled to be presented during the conference and have not yet been publicly disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567864-en) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SAB Biotherapeutics Unveils Positive Phase 1 Data for SAB-142 in Type 1 Diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSAB Biotherapeutics Unveils Positive Phase 1 Data for SAB-142 in Type 1 Diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SABS\">SAB Biotherapeutics</a> Unveils Positive Phase 1 Data for SAB-142 in Type 1 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SABSW\">SAB Biotherapeutics</a> Inc. has announced that new data on its lead candidate, SAB-142, will be presented at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD), taking place November 5-8, 2025, in Montréal, Canada. SAB-142, a fully human anti-thymocyte globulin (hATG), is being developed for the treatment of Stage 3 autoimmune type 1 diabetes. Presentations will include data from a Phase 1 study highlighting the therapy's clinically validated, multi-specific mechanism of action and sustained immunomodulation, as well as its favorable safety profile, with no serum sickness or anti-drug antibodies observed at the target dose. Additional presentations will cover a novel pharmacokinetic assay for SAB-142, its binding specificities, and specimen quality in multicenter clinical trials. The results are scheduled to be presented during the conference and have not yet been publicly disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567864-en) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL9bqv84:1","article_id":"2580732458","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580732458","pubTimestamp":1762263032,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SAB Biotherapeutics Inc. has announced that new data on its lead candidate, SAB-142, will be presented at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes , taking place November 5-8, 2025, in Montréal, Canada. SAB-142, a fully human anti-thymocyte globulin , is being developed for the treatment of Stage 3 autoimmune type 1 diabetes. Presentations will include data from a Phase 1 study highlighting the therapy's clinically validated, multi-specific mechanism of action and sustained immunomodulation, as well as its favorable safety profile, with no serum sickness or anti-drug antibodies observed at the target dose. Additional presentations will cover a novel pharmacokinetic assay for SAB-142, its binding specificities, and specimen quality in multicenter clinical trials. The results are scheduled to be presented during the conference and have not yet been publicly disclosed.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SABS":"SAB Biotherapeutics, Inc.","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股"},"translate_title":"SAB Biotherapeutics公布SAB-142治疗1型糖尿病的积极1期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SABS":0.9},"content_text":"SAB Biotherapeutics Unveils Positive Phase 1 Data for SAB-142 in Type 1 Diabetes\n    \n\nSAB Biotherapeutics Inc. has announced that new data on its lead candidate, SAB-142, will be presented at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD), taking place November 5-8, 2025, in Montréal, Canada. SAB-142, a fully human anti-thymocyte globulin (hATG), is being developed for the treatment of Stage 3 autoimmune type 1 diabetes. Presentations will include data from a Phase 1 study highlighting the therapy's clinically validated, multi-specific mechanism of action and sustained immunomodulation, as well as its favorable safety profile, with no serum sickness or anti-drug antibodies observed at the target dose. Additional presentations will cover a novel pharmacokinetic assay for SAB-142, its binding specificities, and specimen quality in multicenter clinical trials. The results are scheduled to be presented during the conference and have not yet been publicly disclosed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567864-en) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580732458","isCrawlerRequest":true}